Teleflex Inc. has declared a quarterly dividend and raised its financial outlook for 2025, citing strong financial performance and a growing demand for medical devices.

Teleflex Inc. reported mixed financial results for Q1 2025, with revenue declining 3.8% but non-GAAP EPS exceeding expectations, amidst regulatory milestones and strategic initiatives.

Teleflex Inc. has received FDA clearance for its QuikClot Control+ device, allowing it to be used for all grades of internal and external bleeding, expanding its application in various medical procedures.